People given AstraZeneca's Covid jab are LESS likely to develop antibodies than those who receive Pfizer's, major surveillance study suggests
Elderly Britons jabbed with AstraZeneca's vaccine are less likely to have Covid antibodies than those who given Pfizer's, a study has suggested. Imperial College London experts found that fewer than 85 per cent of over-80s had detectable levels of the virus-fighting proteins two weeks after their second AZ jab. By contrast, the proportion of over-80s with antibodies after getting the second Pfizer vaccine was almost 98 per cent. The findings came from Britain's largest surveillance study, known as REACT-2, which randomly tests blood samples from hundreds of thousands of Britons. Although antibodies are just one part of the overall immune response to Covid, experts said they were not totally surprising. Professor Ian Jones, a virologist at Reading University, told MailOnline the British jab was less likely to spark immunity because it relied on a weakened cold virus. In some cases the body may attack this virus instead of the Covid proteins on its surface, which results